Analyses supporting the use of digitalis glycosides in patients with heart failure were presented in a Late-Breaking Science session today at Heart Failure 2026.
Placebo-controlled evidence across 9013 patients showed a lower composite risk (HR 0.85) driven by reduced worsening HF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results